- SureLeaf will assess patients aged 25 and over with eligible chronic pain conditions, generalised anxiety disorder or insomnia.
- Patients must have tried conventional treatments without achieving adequate symptom relief and undergo specialist clinical assessment.
- Boots is exploring a research collaboration with the University of Nottingham to examine medical cannabis outcomes in chronic pain treatment.
Boots has launched a private medical cannabis service through its online healthcare platform, offering specialist assessment and treatment for eligible patients living with chronic pain, generalised anxiety disorder and insomnia.
Called SureLeaf, the service will provide consultant-led assessments, prescribing where clinically appropriate and ongoing monitoring for patients aged 25 and over. It is intended for people whose symptoms have not been adequately relieved by conventional treatments.
The launch expands the range of specialist healthcare available through Boots Online Doctor, which provides private consultations, prescriptions and testing services for more than 45 conditions.
Patients can begin the assessment process online, but suitability will be reviewed by the clinical team before they progress to a video consultation with a consultant in the relevant medical specialty. The consultant must be listed on the General Medical Council's Specialist Register.
Any proposed prescription will also undergo independent review by a multidisciplinary clinical team, including a second consultant, before treatment begins.
Jamie Kerruish, chief healthcare officer at Boots, said the service was intended to give eligible patients another treatment option where conventional treatments had not provided adequate symptom relief.
He said ongoing pain could affect everyday activities, including working, sleeping and spending time with family, adding that the service would combine specialist expertise with continued clinical care.
How will Boots assess and monitor patients?
SureLeaf will cover a range of conditions, including chronic primary and neuropathic pain, fibromyalgia, complex regional pain syndrome, chronic back and neck pain, osteoarthritis, rheumatoid arthritis, sciatica, peripheral neuropathy, trigeminal neuralgia, phantom limb pain, chronic migraine, endometriosis-related pelvic pain and chronic abdominal or pancreatic pain.
Generalised anxiety disorder and insomnia disorder are also included in the service's eligibility criteria.
Patients will receive clinical support throughout treatment, with an initial review after 28 days and further assessments at least every three months.
Validated questionnaires will be used to monitor areas including quality of life, pain, anxiety, sleep and mood. These assessments are intended to help clinicians evaluate individual outcomes and review whether treatment remains appropriate.
Dr David Gwynne, medical director at Boots Online Doctor, said medical cannabis was not suitable for everyone and that prescribing decisions needed to be made on an individual basis.
He said SureLeaf had been designed with clinical safeguards and specialist oversight, from the initial assessment through to ongoing monitoring.
The service will operate privately through Boots Online Doctor and is not an NHS treatment programme.
What is Boots planning for medical cannabis research?
Alongside the launch, Boots is exploring a collaborative research programme with the University of Nottingham to examine the use of medical cannabis in chronic pain management.
The proposed work would investigate patient outcomes, prescribing practices and patient experiences, building on the existing relationship between the two organisations.
Boots said the research could contribute to the wider understanding of medical cannabis and help inform future clinical practice and the development of the service.
However, the collaboration is still being explored. No confirmed research protocol, start date or study findings have been announced.
The launch comes as medical cannabis remains a specialist area of treatment requiring individual clinical assessment. Boots' approach places eligibility checks, independent review and continued monitoring at the centre of its service.
Further information on eligibility and access is available through the SureLeaf service page on Boots Online Doctor.












